PATIENT STORIES

Parker and Alexia – Diagnosed with PANDAS

At age 11, Parker suddenly developed tics, mood swings and seizure-like episodes (Part 2).

Parker’s Story (Part 2)

In 4th grade, Parker suddenly began having tics, mood swings, outbursts of rage and seizures. After months of searching for an answer, he was diagnosed with PANDAS.

WATCH VIDEO: PARKER’S STORY

Source: ABC News

Spring came late to Minnesota this year. The land of 10,000 lakes still frozen, long past usual but in the pleasant town of Prior Lake, April marked a year since the Barnes family's lives changed forever.

Reporter:
Before all this hit what was your family life like?

Parents:
4 kids, 2 dogs, lots of love, lots of laughs, lots of giggles. 

Kids talking to each other:
You used to do truth or dare since you were 4 years old. We never did that.

Reporter:
11-year-old Parker, the oldest [child].

Parker:
My nickname that my mom and dad call me is “lead dog.”

Reporter:
A rambunctious, outgoing boy until midway through 4th grade. Parker started acting differently - odd tics, strange moodiness. But then, something much worse. It's hard to watch.

Parents:
You're in control Parker. Look at mom.

Reporter:
Harder still when you consider that Natalie and Brian were watching their son suffer with seizures like these for months. Heart-wrenching and without warning.

Mom:
[Parker having seizure] It’s okay Parker, we got you. We right here with you.

Dad:
I would liken it mostly to an abduction. Something came in the window and stole our child and left behind this shell. Our kid is gone.

Parker:
I was the first one to see it. But Parker's brother Stetson witnessed one of the worst episodes one day while heading up the stairs to the bathroom. He ran into Parker brandishing a kitchen knife.

Parents:
We ran up to the bathroom and he was standing there with a knife in his hand. I just grabbed the knife and I'm just hugging him.

Reporter:
That day with the knife, did you want to hurt yourself?

Parker:
I don’t really know.

Reporter:
It's as if you can't even recognize your own child and yet no doctor is able to give you answers?

Parents:
Their recommendation was - he needs to be evaluated by a psychiatrist.

Reporter:
It's a psychiatric condition?

Parents:
Yeah.

Reporter:
The barns were dumbstruck to be checking their child into a psychiatric hospital.

Parker:
That was a nightmare. It was like a prison for children because all the children there didn't want to see their families because they were all angry and mean or something.

Reporter:
But while Parker was being evaluated, suddenly a curious coincidence. A doctor was struck when she learned that when Parker's symptoms first began all those months ago he had just been diagnosed with something else - strep throat. It was a Eureka moment.

Mom:
She said he might have something called PANDAS.  And we're like PANDAS?

Reporter:
Parents get the answer PANDAS and their reaction is “What PANDAS?” If you’ve never heard of PANDAS, you're hardly alone. In fact, no one had heard of it before this woman - Dr. Susan Swedo of the National Institute of Mental Health first identified it 20 years ago.

Dr. Swedo:
I study children and try and understand what's wrong with them and how to help them.

Reporter:
While it conjures up images of the cute and cuddly bears, PANDAS is actually an acronym for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Strep infections. What is PANDAS?

Dr. Swedo:
In its simplest form - the wrong strep in the wrong kid impacts the brain and gives rise to behavioral symptoms.

Reporter:
How? Swedo says normally when children get strep their immune system creates antibodies to fight the infection but with certain kids the immune system malfunctions. Those antibodies start attacking healthy cells. And even worse, they sneak across what's called the “blood-brain barrier” that is designed to protect the brain.

Dr. Swedo:
It’s designed to protect the brain. But we now know that the blood-brain barrier can become leaky.

Reporter:
It's as if the antibodies are attacking the brain.

Dr. Swedo:
In a way, yes.

Reporter:
And once the brain is invaded, Swedo says, that's when children can very rapidly exhibit a wide range of psychiatric and neurological problems. Some as severe as the kind Parker had.

Dr. Swedo:
So, traditional onset OCD is gradual, comes over a period of days or weeks. PANDAS OCD comes on overnight. A medical lightening strike.

Alexia’s Parents:
The only thing that kept questioning is, “Why did this suddenly come on? Wouldn't I have seen signs? And what about that strep? [Dr. Swedo’s] research is striving to figure it out and it really paid off.

Reporter:
Eventually, a neuropsychologist made a connection between the strep and immediate onset of symptoms that made sense to the Baier family.

Parents:
She asked, Have you ever heard of PANDAS?

Reporter:
Is it fair to say you were relieved?

Parents:
Definitely relieved to have some sort of diagnosis that made sense.

Parker’s Parents:
I’m thinking great, PANDAS. What do you do? Whatever it is, great, it will be gone and we’ll get our kid back.

View Alexia's Story
View Grace's Story
View Julie's Story
View Sunny's Story
Read Physician Testimonials about the Cunningham Panel

LEARN MORE: AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS

PANS: Diagnosis and Treatment

PANS/PANDAS Overview

PANDAS & PANS Patient Stories

PANDAS & PANS Patient Stories

Neuropsychiatric Symptoms

Neuropsychiatric Symptoms

  • Test Order Process
    The Cunningham Panel™ – Antibody testing that helps determine whether an autoimmune response may be triggering neurologic and/or psychiatric symptoms.

B. Robert Mozayeni, MD

Medical and Clinical Advisor

B. Robert Mozayeni MD

Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).

He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.

Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)

Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO

Sajo Baqaj, PhD

Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.

Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.

Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.

Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.

He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.

Rodney Cotton, MBA

Moleculera Labs Board Member

Rodney Cotton, MBA

Rodney Cotton, MBA is an entrepreneurial thought leader in the pharmaceutical/biotech industry who is known for his holistic perspective, bias for action in the face of challenges, and commitment to agile processes.

Rod is an independent director for Orchard Software, a private equity-backed health technology company owned by Francisco Partners; an advisory board member to Flo2 Ventures, a venture capital-backed healthcare and health equity accelerator; and a member of the board of directors and three board committees (Audit, Compliance & Finance; Governance & Equity; and Quality of Care) for Community Health Network.

He built a successful career at Roche spanning more than two decades and culminating in the role of SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO for Roche Diagnostics, the North American headquarters of the world’s largest ($17B) diagnostics company.

While at Roche, Rod led key enterprise initiatives, such as milestone corporate communications, health equity coalitions, the US/Roche Group audit, and global/US acquisition integrations. With 40+ years of experience, he drove the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 total reports, managed P&L of more than $1 billion, and served as a key member of the senior leadership team executing the most significant restructuring of the company in two decades.

In the face of the COVID-19 pandemic, Rod and his team at Roche accelerated six ground breaking products in 11 months, including the first launch of the market’s most accurate and in demand molecular diagnostic test. He also solved extraordinary challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self manufacturing in line with testing guidelines.

A frequent public speaker on health equity and other topics, Rod was named one of the Most Influential Black Executives in Corporate America by Savoy Magazine and one of the Top Blacks in Healthcare by BlackDoctor.org. He also received The Sagamore of the Wabash Award, one of the highest Indiana State honors, bestowed by Indiana Governor Eric J. Holcomb.

Rod holds an M.B.A. from California State University, Dominguez Hills, an M.S. in Strategic Management from the University of Southern California, and a B.A. in Biological Sciences & Technology from the University of California at Santa Barbara.